Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMUQ6IL)

Drug Name
AVE-1642 Drug Info
Synonyms
EM-164; Anti-IGF-1 receptor antibody (cancer), Aventis; Anti-IGF-1 receptor antibody (cancer), ImmunoGen; Anti-insulin-like growth factor-1 receptor antibody, Aventis; Anti-insulin-like growth factor-1 receptor antibody, ImmunoGen; Anti-IGF-1 receptor antibody (cancer), sanofi-aventis; Anti-insulin-like growthfactor-1 receptor antibody, sanofi-aventis
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Discontinued in Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMUQ6IL

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin-like growth factor I receptor (IGF1R) TTHRID2 IGF1R_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Insulin-like growth factor I receptor (IGF1R) DTT IGF1R 4.542 5.508 6.35 5.558
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Insulin-like growth factor I receptor (IGF1R) DTT IGF1R 1.64E-01 0.25 0.64
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021953)
2 Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growthfactor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5445-56.